In the past week, TAK stock has gone up by 2.42%, with a monthly gain of 2.76% and a quarterly surge of 3.87%. The volatility ratio for the week is 0.92%, and the volatility levels for the last 30 days are 0.97% for Takeda Pharmaceutical Co ADR The simple moving average for the last 20 days is 2.47% for TAK stock, with a simple moving average of 8.66% for the last 200 days.
Is It Worth Investing in Takeda Pharmaceutical Co ADR (NYSE: TAK) Right Now?
The price-to-earnings ratio for Takeda Pharmaceutical Co ADR (NYSE: TAK) is 71.08x, which is above its average ratio. Moreover, the 36-month beta value for TAK is 0.27. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price recommended by analysts for Takeda Pharmaceutical Co ADR (TAK) is N/A, which is -$2249982.7 below the current market price. The public float for TAK is 3.15B and currently, short sellers hold a 0.21% of that float. On July 01, 2025, TAK’s average trading volume was 2.25M shares.
TAK) stock’s latest price update
Takeda Pharmaceutical Co ADR (NYSE: TAK) has seen a decline in its stock price by -0.10 in relation to its previous close of 15.46. However, the company has experienced a 2.42% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-06-30 that OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD.
Analysts’ Opinion of TAK
Many brokerage firms have already submitted their reports for TAK stocks, with Morgan Stanley repeating the rating for TAK by listing it as a “Overweight.” The predicted price for TAK in the upcoming period, according to Morgan Stanley is N/A based on the research report published on April 02, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see TAK reach a price target of $20. The rating they have provided for TAK stocks is “Buy” according to the report published on March 16th, 2023.
Cowen gave a rating of “Outperform” to TAK, setting the target price at $24 in the report published on July 19th of the previous year.
TAK Trading at 3.93% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -0.23% of loss for the given period.
Volatility was left at 0.97%, however, over the last 30 days, the volatility rate increased by 0.92%, as shares surge +2.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.20% upper at present.
During the last 5 trading sessions, TAK rose by +2.62%, which changed the moving average for the period of 200-days by +4.42% in comparison to the 20-day moving average, which settled at $15.07. In addition, Takeda Pharmaceutical Co ADR saw 19.64% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TAK starting from Giles Richard Platford, who proposed sale 19,073 shares at the price of $14.94 back on Aug 23 ’24. After this action, Giles Richard Platford now owns N/A shares of Takeda Pharmaceutical Co ADR, valued at $284,951 using the latest closing price.
N/A, the N/A of Takeda Pharmaceutical Co ADR, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.55 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.02. The total capital return value is set at 0.04. Equity return is now at value 1.50, with 0.73 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 2.1.
Currently, EBITDA for the company is 874.6 billion with net debt to EBITDA at 3.57. When we switch over and look at the enterprise to sales, we see a ratio of 2.41. The receivables turnover for the company is 6.32for trailing twelve months and the total asset turnover is 0.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.01.
Conclusion
To wrap up, the performance of Takeda Pharmaceutical Co ADR (TAK) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
